Epstein-Barr virus induced myositis in a patient with mitochondrial diabetes

Authors

• Anna Kyriakidou Royal Free Foundation Trust, Barnet Hospital, London, UK
• Anastasia Papapostolou Alithias Endocrinology Center, Nicosia, Cyprus; European University, Nicosia, Cyprus
• Michalis Picolos Alithias Endocrinology Center, Nicosia, Cyprus; European University, Nicosia, Cyprus

picolos_endocrine@yahoo.com

Keywords

Abstract

Epstein-Barr virus (EBV) is a rare but well-known trigger for acute myositis. Diagnosis is primarily based on the clinical presentation and an accounting laboratory profile. Patients with mitochondrial dysfunction are potentially at a higher risk of myopathic exacerbations upon exposure to acute insults. This is due to the high energy requirements of myofibers and their reliance on sufficient mitochondrial performance. Hence, any mitochondrial insult can compromise the function of myofibers. This has implications on the management of people with pre-existing mitochondrial dysfunction, with scope for preventative measures and a lower threshold for diagnosis of myopathies. Usually, management is limited to conservative measures. Medications which predispose to muscle injury need to be withheld during the acute episode and their long-term need reviewed based on a risk-benefit analysis. Here, we present a case of acute EBV-induced myositis on a background of maternally inherited diabetes and deafness and chronic statin intake.

References